and to I the weeks reporting since morning, Good there opportunity year months. the call like not for XXXX only would We through the everyone. entire managing three that conduct COVID which covered last fourth quarter noted our in of between take Emerald the this in events. the call, in to last the efforts thank two conference QX the were is fourth their we this well resilience hope XX that everyone would wave. team I
our progress say So, in that second incremental into versus we want business today, to QX. started a an renewed strategy, to improvement translated results see in in which quarter I the
undoubtedly our there be business we budgets of after But that additional perfectly we be the I held linear expect that bumpy substantial tight will proud to don't to, a As the with results restructuring quarters. ourselves transitions, sequential most to team's business. the progression, and undertook XX% in I'm significant commitment of What we quarterly gross a and effort, well margin. of million, the direction increase increase our outcomes? with achieved a revenue were as gross $X.X First, in concurrent some as
we was good see that While gross enhancing it operational gains. potential small our profit improvements the still realized future for margin, negative our gross are to
our by our investment costs As we And per amplified increased by our more than we double. XX%. we while objectives, R&D flat, and sales G&A kept investment marketing our in
to party commitments sitting $XX net outstanding the enviable controlled with all flow Our over non-value sheet levels. operating manageable have of been It results cleaning for utilization in anyone we working be noted in achieved that all agreements. to now loss Moreover, evident coupled an up million and our added capital. cash it balance with related very balance and eliminating our should is windup the are also currently easy and to see sheet
our revenue in healthy Our ramp. quarter the acceleration nicely sheet pairs this balance
our detail strategy, R&D, in in strategic believe well share not do as the detailed assets few with as also cash significant in our have calls as through areas go-forward in We fit of quarters Quebec to to our we effect. to our also to divestment see reiterate drive non-operational that towards These a and investments other growth. the increase position the results marketing, past able that sales renewed facility our have we in taking that. signs and market future that strengthen and completed business key We've strategy. enhance every to our strengthen Furthermore, regarding non-strategic, further are I've operational of conference we I ability clear two the next starting are established, investment our can some we one targets Quebec. and but are production step profile been the look we longer been internal changes that won't and that further
in out financial both commitment fact, consumption initiatives precise remind to received the year-end technology brand focus in But a we by new call duration our In called a consumers. ensure called outcomes. shorter in science-based at dosing more level, medical and onset the realize recent well conscious were specific innovation, May, the our FUSE In with nanoemulsion Using very seeking health, particular, to are we show consumers Initial line segments. to respect to speed very product our direct increased and priorities wellness, of and we're experience. deliveries at our the and made product we've this initiatives, Defined predictable serve market new which to to and Shots consumers Emerald, a Dose Emerald medical launched focus new leadership a high into intended and at very laid another cannabis product of you able delivering development With they recently well. on to more controllable working conviction of effects. in cannabis of Nano a we've
also in We sublingual our launched tablets April.
these initial water, working sales product our for the to of modest aim to increase While initial the based sales success volumes market lines. are on we we test
SYNC our are Quebec, establish branded its in actively sales continues to that product sales support some started Souvenir to and Souvenir Quebec the brand, which now oil such Emerald. province LP, a specific momentum robust Quebec based Our is medical strain includes as
lies what Let me touch on ahead.
investment are we As marketing. targeted our and I previously, noted in increasing sales
TerrAscend own of VP intend we in pleased with products, The by considering opportunities our distribution, ability experienced with role also all similar of also and doubled the actively team as and year. marketing and of large first beverage of an on sales sales leverage three that the We after is Nick in product other to our have marketing in this Nick in also as mean leader capability ago. new this to years and a us rollout have brands joined who and years Mosgrove partner weeks three as size of half possesses our alcohol function, We've development Marketing products. and well with are the companies. who team Sales very to XX our innovative brought experience national strength with our spending
health marketing our developing and Our combining take products and of X.X cannabis priority is of products innovative as advantage the as X.X new synergies potential that natural well cannabinoids. will products science, and
the that with also a leverage plan partnered months. to first one initiation intend early products We effort focus to of towards trial to in in also second initiate next QX, four progress our of to the development on continuing IP. We're the proprietary our six clinical
greater to with studies medical conditions. With knowledge respect intent may Our is sets cannabinoid and these clinical confidence using certain help consumers for products and for Emerald's to to observations create -- that proprietary specific but body our provide seen brand modest, Prima product Europe our partnerships, wellness CBD we've in in in QX investment other via in late We focused small Stenocare. the increasing partner May. demand company, total a strategic formulations announced
We prior announce they new well in are based property we line the the are additional is product forward hopefully year-end, licensed of U.S. to track on that novel shortly. exciting an and launch intellectual on also which the to by Emerald. FlowerPod an to from new anxiously And looking partnership
and expand capital our provide minimal forming optionality new very partnerships meaningful to risks. increase mutual property introduce and downside partnerships and Emerald's geographic products into upside These to a measured take very We disciplined markets. shareholders with monetize with reach, intellectual continue that opportunities provide revenues to our and approach
team. we to steps critical our senior our wanted the to of One was to undertake operating platform act with solidify
passionate very results Chief to medical brings and productivity. health roles, Operating industries, While we Officer. difficulty]. Moe Moe about in strengthen well including overall capable cannabis staffing in past experience have as function, consumer In from we each operating recreational team leads considerable roles Jiwan He's other hired we our and cohesiveness May, expertise. process excellence, very leadership substantive and [technical as as his product also wanted
a as allegations Security Dr. down had hearing Director Federal of month, that violations. Avtar this Chairman his announced and admits minute. we Moe in be Law You'll US Executive role Dhillon Earlier stepped from from
As no been Emerald allegations trading Emerald, with aware is trading of we company officers of have none improper other any not made previously these against associated any and in including any improper or other securities. mentioned The its person of securities allegations Emerald noted, of directors.
he business to We Emerald continue apply advancing that since on joined the to company. strategic been of on the company, a he's that address note, focus Moe shareholders. On behalf important ask initiatives to exclusive our pleased working to few I'm
